Augment with Memantine
Phase 2Small molecule
Augment with Memantine is one of 46 small molecule programs targeting Obsessive-Compulsive Disorder. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Obsessive-Compulsive Disorder
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Ingrezza
Neurocrine BiosciencesApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Celexa
AbbVieApproved
Revia
TevaApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Zoloft
VViatris Specialty LLC
Approved
Topamax
WWim Janssens
Approved
Tasmar
BBausch Health Americas, Inc.
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Augment with Memantine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Mental Health Center